Position history for RA CAPITAL MANAGEMENT, L.P.'s holdings in 4D MOLECULAR THERAPEUTICS IN
RA CAPITAL MANAGEMENT, L.P. holds 5.7M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $42.4M as of 2025-Q4. The position was increased (++23.9% shares). FDMT represents 0.4% of RA CAPITAL MANAGEMENT, L.P.'s portfolio.
Current Value
$42.4M
Current Shares
5.7M
Total Value Change
-$64.6M
Total Shares Change
+555,000
Other major holders of FDMT: UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, VIKING GLOBAL INVESTORS LP
Increased |
| 5.7M |
+23.9% |
| $42.4M |
| 0.4% |
| $7.58 |
42 |
| 2025-Q3 | Unchanged | 4.6M | 0.0% | $39.7M | 0.5% | $8.35 | 0 |
| 2025-Q2 | Unchanged | 4.6M | 0.0% | $16.9M | 0.3% | $3.84 | 0 |
| 2025-Q1 | Unchanged | 4.6M | 0.0% | $14.7M | 0.2% | $3.63 | 0 |
| 2024-Q4 | Decreased | 4.6M | -10.5% | $25.4M | 0.3% | $5.30 | 0 |
| 2024-Q3 | Unchanged | 5.1M | 0.0% | $55.1M | 0.6% | $10.83 | 0 |
| 2024-Q2 | Increased | 5.1M | +0.9% | $107M | 1.4% | $20.99 | 48 |